OverviewSuggest Edit

ACell is a regenerative medicine company focused on the development, manufacturing, and commercialization of medical devices for wound management and surgical soft tissue repair. It offers MatriStem UBM (Urinary Bladder Matrix) technology that facilitates the body's ability to remodel functional tissue.
TypePublic
Founded2002
HQColumbia, MD, US
Websiteacell.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Mar 2020)400
Revenue (FY, 2019)$100.8 M(+13%)
Cybersecurity ratingCMore

Key People/Management at ACell

Patrick A. McBrayer

Patrick A. McBrayer

President and Chief Executive Officer, Director
Chris Branch

Chris Branch

Chief Operating Officer
Matthew Kunst

Matthew Kunst

Treasurer and Chief Financial Officer
Nino Pionati

Nino Pionati

Chief Commercial Officer
Bill Hrubes

Bill Hrubes

Chief Compliance Officer
Sue Sutton-Jones

Sue Sutton-Jones

Vice President, Regulatory Affairs and Quality
Show more

ACell Office Locations

ACell has offices in Columbia and Lafayette
Columbia, MD, US (HQ)
6640 Eli Whitney Dr # 200
Lafayette, IN, US
3589 Sagamore Pkwy N
Show all (2)

ACell Financials and Metrics

ACell Revenue

Embed Graph
View revenue for all periods
ACell's revenue was reported to be $100.79 m in FY, 2019 which is a 13% increase from the previous period.
USD

Revenue (FY, 2019)

100.8m

Revenue growth (FY, 2018 - FY, 2019), %

13%

Gross profit (FY, 2019)

81.7m

Gross profit margin (FY, 2019), %

81%

Net income (FY, 2019)

1.4m

EBIT (FY, 2019)

1.4m

Cash (31-Dec-2019)

7.0m
USDFY, 2018FY, 2019

Revenue

89.2m100.8m

Revenue growth, %

13%

Cost of goods sold

16.3m19.1m

Gross profit

72.9m81.7m
USDFY, 2018FY, 2019

Cash

7.7m7.0m

Accounts Receivable

12.2m13.6m

Prepaid Expenses

1.7m2.8m

Inventories

8.7m8.9m
USDFY, 2018FY, 2019

Net Income

(3.1m)1.4m

Depreciation and Amortization

2.2m2.3m

Inventories

(1.9m)(246.4k)

Accounts Payable

195.6k451.3k
USDFY, 2018

Debt/Equity

0.1 x

Financial Leverage

2.6 x
Show all financial metrics

ACell Operating Metrics

ACell's Customers was reported to be 1.9 k in FY, 2019.
FY, 2019

Countries

11

Customers

1.90 k

Patents (US)

36

Product Lines

3
Show all operating metrics

ACell Revenue Breakdown

Embed Graph

ACell revenue breakdown by business segment: 77.7% from Wound and 22.3% from Surgical

ACell Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

ACell Online and Social Media Presence

Embed Graph

ACell News and Updates

Integra LifeSciences Completes the Acquisition of ACell, Inc.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc

ACell Announces CE Mark Approval

COLUMBIA, Md., Dec. 22, 2020 /PRNewswire/ -- ACell, Inc., a leading regenerative medicine company, announced today that it has received CE mark approval for its MicroMatrix®, Cytal® Wound Matrix, and Cytal® Burn Matrix devices. This regulatory approval allows ACell to distribute these...

Integra LifeSciences Announces Definitive Agreement to Acquire ACell, Inc.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) a leading global medical technology company, today announced it has entered into a definitive agreement to acquire ACell, Inc. (“ACell”) for an upfront cash payment of $300 million at closing, subject to customary purchase price adjustments, an…

South and Central America Extracellular Matrix Market Demand, Segmentation, Recent Trends, Strategies To 2027 | Top Players Like Organogenesis Inc., Integra Life Sciences Corporation, Mölnlycke Health Care AB, Anika Therapeutics, Inc., ACell Inc.

The South and Central America extracellular matrix market was valued at US$ 989.99 thousand in 2019 and is projected to reach US$ 11,708.44 thousand by 2027; it is expected to grow at a CAGR of 7.1% from 2020 to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

ACell Launches Roadshow for Initial Public Offering

ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has …

ACell Launches Gentrix Hiatal at Society of Laparoendoscopic Surgeons Meeting

ACell, Inc. today announced the launch of their new product, Gentrix® Hiatal at the 2019 Society of Laparoendoscopic Surgeons (SLS) Minimally Invasive Surgery Week 2019 (MISWeek 2019) in New Orleans, Louisiana. Gentrix Hiatal provides physicians a new solution for hiatal hernia repair and reinforcem…
Show more

ACell Blogs

Integra LifeSciences Announces Definitive Agreement To Acquire ACell, Inc.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) a leading global medical technology company, today announced it has entered into a definitive agreement to acquire ACell, Inc. (“ACell”) for an upfront cash payment of $300 million at closing,... The post Integra LifeSciences Announces Definiti…

ACell Frequently Asked Questions

  • When was ACell founded?

    ACell was founded in 2002.

  • Who are ACell key executives?

    ACell's key executives are Patrick A. McBrayer, Chris Branch and Matthew Kunst.

  • How many employees does ACell have?

    ACell has 400 employees.

  • What is ACell revenue?

    Latest ACell annual revenue is $100.8 m.

  • What is ACell revenue per employee?

    Latest ACell revenue per employee is $252 k.

  • Who are ACell competitors?

    Competitors of ACell include Osiris Therapeutics, Xtant Medical and Acelity.

  • Where is ACell headquarters?

    ACell headquarters is located at 6640 Eli Whitney Dr # 200, Columbia.

  • Where are ACell offices?

    ACell has offices in Columbia and Lafayette.

  • How many offices does ACell have?

    ACell has 2 offices.